Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
January 04 2017 - 9:40PM
Business Wire
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the
underwriters of its recently announced public offering of its
common stock have exercised in full their option to purchase an
additional 750,000 shares.
The offering, including the sale of the additional shares, is
expected to close on January 9, 2017, subject to customary closing
conditions.
Clovis Oncology intends to use the net proceeds of the offering
for general corporate purposes, including commercial planning and
sales and marketing expenses associated with the launch of Rubraca™
(rucaparib) in the United States and, if approved by the European
Medicines Agency (EMA), in Europe, funding of its development
programs, general and administrative expenses, acquisition or
licensing of additional product candidates or businesses and
working capital.
J. P. Morgan Securities LLC and BofA Merrill Lynch are acting as
joint book-running managers for the offering. Stifel and SunTrust
Robinson Humphrey are acting as co-managers for the offering.
The shares of Clovis Oncology common stock described above are
being offered only by means of a prospectus supplement and related
prospectus pursuant to an effective shelf registration statement
previously filed with the Securities and Exchange Commission.
Copies of the final prospectus supplement and related prospectus
relating to this offering may be obtained from J. P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717 or by calling toll-free (866)
803-9204, or from BofA Merrill Lynch, NC1-004-03-43, 200 North
College Street, 3rd floor, Charlotte NC 28255-0001, Attn:
Prospectus Department, or by email to
dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer
agents in the U.S., Europe and additional international markets.
Clovis Oncology targets development programs at specific subsets of
cancer populations, and simultaneously develops diagnostic tools
that direct a compound in development to the population that is
most likely to benefit from its use. Clovis Oncology is
headquartered in Boulder, Colorado.
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Clovis Oncology,
they are forward-looking statements reflecting the current beliefs
and expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve substantial risks and
uncertainties that could cause our actual results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the timing and size of the
offering, the conditions affecting the capital markets, general
economic, industry, or political conditions, and the satisfaction
of customary closing conditions related to the proposed public
offering. Clovis Oncology undertakes no obligation to update or
revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to the business of the company in general,
see the prospectus supplement and related prospectus for this
offering as well as Clovis Oncology’s Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and its other reports filed with the
Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170104006579/en/
Clovis OncologyAnna Sussman,
303-625-5022asussman@clovisoncology.comorBreanna Burkart,
303-625-5023bburkart@clovisoncology.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Apr 2023 to Apr 2024